Related Funds
| Fund Name | Location |
| 212 | Istanbul, Istanbul, Turkey |
| Clickky | New York, New York, United States |
| Codding Enterprises | California, Rohnert Park, United States |
| Dajiatou | China, Guangdong, Shenzhen |
| First Plaza Group Trust | Pennsylvania, Pittsburgh, United States |
| FPT Group | - |
| LeFrak | New York, New York, United States |
| Liquid Capital Group | England, London, United Kingdom |
| Maliang New Material | China, Hangzhou, Zhejiang |
| Netherlands Enterprise Agency | Assen, Drenthe, The Netherlands |
| Prime Mont V.C | Beijing, Beijing, China |
| Purple Ventures Management Consultant LLP | India, Maharashtra, Mumbai |
| RM Global Partners | New York, New York, United States |
| Shrem | Andheri, India, Maharashtra |
| SV Investment Corp | Seoul, Seoul-t'ukpyolsi, South Korea |
| Wainbridge Capital | England, London, United Kingdom |
| XIM | California, San Francisco, United States |
| Yi Pu Tou Zi | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Hillhurst Biopharmaceuticals | 20 Dec 2023 | San Diego, California, United States | |||
Trio Pharmaceuticals | $2M | 28 Mar 2023 | San Diego, California, United States | ||
PetDx | $62M | 09 Dec 2021 | San Diego, California, United States | ||
DTx Pharma | $100M | 01 Mar 2021 | San Diego, California, United States | ||
PetDx | $10M | 01 Jun 2020 | San Diego, California, United States | ||
DTx Pharma | $10M | 06 Jan 2020 | San Diego, California, United States | ||
DTx Pharma | $3M | 14 May 2019 | San Diego, California, United States | ||
MedCrypt | $1M | 28 Jun 2018 | California, United States |
– DTx Pharma, Inc. from San Diego raised $100m in Series B financing.
– The round was led by RA Capital Management with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital and existing investors Friedman Bioventure Fund, Eli Lilly and Company, Viva BioInnovator (Viva Biotech Holdings, 1873.HK), and ExSight Ventures.
– The company intends to use the funds to utilize its FALCON fatty acid motifs to advance assets into clinical development across several therapeutic areas over the next few years.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Hillhurst Biopharmaceuticals | 20 Dec 2023 | San Diego, California, United States | |||
Trio Pharmaceuticals | $2M | 28 Mar 2023 | San Diego, California, United States | ||
PetDx | $62M | 09 Dec 2021 | San Diego, California, United States | ||
DTx Pharma | $100M | 01 Mar 2021 | San Diego, California, United States | ||
PetDx | $10M | 01 Jun 2020 | San Diego, California, United States | ||
DTx Pharma | $10M | 06 Jan 2020 | San Diego, California, United States | ||
DTx Pharma | $3M | 14 May 2019 | San Diego, California, United States | ||
MedCrypt | $1M | 28 Jun 2018 | California, United States |
